Olink Proteomic Biomarker Discovery Tech Note

Proteomic Biomarker Discovery to Support Clinical Trials Using High Plex Olink PEA Technology

Historically, preclinical exploratory research and clinical trial biomarker detection have been restricted to a limited number of protein indicators measured by mass spectrometry and ELISA (enzyme-linked immunosorbent assay). These traditional approaches often constrain the ability to evaluate complex biological responses across multiple pathways due to limited plex capacity and higher sample requirements.

Using Olink® Proximity Extension Assay (PEA) technology, GENEWIZ from Azenta Life Sciences delivers fully validated protein biomarker discovery services that enable higher-plex and scalable protein analysis with sensitivity comparable to traditional methods while requiring low sample input. This approach expands access to multiplexed protein biomarker dataacross preclinical research and clinical trial programs.

In this tech note, explore the science behind the Olink PEA assay and learn how this optimized workflow makes it easier to incorporate protein biomarker discovery into preclinical and clinical research.

What You'll Learn

• Discover how high-plex proteomics supports protein biomarker discovery across preclinical research and clinical trials
• Explore the capabilities of multiplexed and high-plex Olink Target Panels for cytokine and inflammatory biomarker profiling
• Review results from GENEWIZ’s supplementary validation study of the Olink Target 48 Cytokine assay, including assay precision, reproducibility, and performance metrics